| Indicators | Browse All

Neuphoria Therapeutics Inc. (NEUP)

Healthcare | Biotechnology | Burlington, United States | NasdaqGM
3.49 USD -0.05 (-1.412%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:50 a.m. EDT

The immediate outlook is bearish due to a sharp price collapse from the $4.50 range to the $3.30-$3.60 zone over the last two weeks, signaling a loss of technical support. While the company holds a fortress-like balance sheet with massive cash reserves relative to debt, the business fundamentals are severely compromised by a complete lack of revenue and a multi-year trajectory of destruction where the stock has lost over 90% of its value in just three years. The market is clearly pricing in a terminal decline or a failed turnaround, rendering any 'value' arguments moot given the structural deterioration. There is no dividend to provide income, and the recent news of acquisition talks offers only speculative hope rather than a confirmed strategic pivot.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.095657
AutoETS0.097366
AutoARIMA0.097416
MSTL0.115554
MSTL_820.124126
MSTL_82_1140.141778
MSTL_1140.174479

Forecast horizon: 60 days | Selected: AutoTheta

Forecast Reliability
Score 26%
H-stat 1.11
Ljung-Box p 0.000
Jarque-Bera p 0.003
Excess Kurtosis 0.71
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.116
Revenue per Share -0.004
Market Cap 18,861,884
Forward P/E -1.44
Previous Name Bionomics Limited
Website https://www.neuphoriatx.com

Info Dump

Attribute Value
52 Week Change -0.5402597
Address1 100 Summit Drive
All Time High 264.0
All Time Low 2.124
Ask 3.41
Ask Size 2
Average Daily Volume10 Day 143,200
Average Daily Volume3 Month 64,985
Average Volume 64,985
Average Volume10Days 143,200
Bid 3.41
Bid Size 1
Book Value 5.472
City Burlington
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.49
Current Ratio 14.312
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 3.57
Day Low 3.405
Debt To Equity 0.116
Display Name Neuphoria Therapeutics
Earnings Timestamp End 1,742,212,800
Earnings Timestamp Start 1,741,863,540
Ebitda -13,998,901
Ebitda Margins 0.0
Enterprise To Ebitda 0.039
Enterprise To Revenue 41.045
Enterprise Value -544,547
Eps Current Year -4.07
Eps Forward -2.43
Eps Trailing Twelve Months -7.9
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.66754
Fifty Day Average Change -1.1775401
Fifty Day Average Change Percent -0.2522828
Fifty Two Week Change Percent -54.02597
Fifty Two Week High 21.4
Fifty Two Week High Change -17.91
Fifty Two Week High Change Percent -0.8369159
Fifty Two Week Low 3.19
Fifty Two Week Low Change 0.29999995
Fifty Two Week Low Change Percent 0.09404387
Fifty Two Week Range 3.19 - 21.4
Financial Currency USD
First Trade Date Milliseconds 1,639,665,000,000
Float Shares 4,186,689
Forward Eps -2.43
Forward P E -1.436214
Free Cashflow -10,218,799
Full Exchange Name NasdaqGM
Full Time Employees 7
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -13,267
Has Pre Post Market Data 1
Held Percent Insiders 0.07703
Held Percent Institutions 0.55032
Implied Shares Outstanding 5,404,551
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ir Website http://www.bionomics.com.au/page.php?section=34
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,751,241,600
Last Split Date 1,734,998,400
Last Split Factor 1:12
Long Business Summary Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Long Name Neuphoria Therapeutics Inc.
Market us_market
Market Cap 18,861,884
Market State PRE
Max Age 86,400
Message Board Id finmb_3331473
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -17,431,132
Next Fiscal Year End 1,782,777,600
Non Diluted Market Cap 19,132,110
Open 3.54
Operating Cashflow -17,152,000
Operating Margins 1,105.1332
Payout Ratio 0.0
Phone 781 439 5551
Prev Name Bionomics Limited
Previous Close 3.54
Price Eps Current Year -0.8574938
Price Hint 4
Price To Book 0.6377924
Price To Sales Trailing12 Months -1,421.7144
Profit Margins 0.0
Quick Ratio 13.907
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.05
Regular Market Change Percent -1.41243
Regular Market Day High 3.57
Regular Market Day Low 3.405
Regular Market Day Range 3.405 - 3.57
Regular Market Open 3.54
Regular Market Previous Close 3.54
Regular Market Price 3.49
Regular Market Time 1,783,972,800
Regular Market Volume 44,920
Return On Assets -0.27971
Return On Equity -0.62904
Revenue Per Share -0.004
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 5,404,551
Shares Percent Shares Out 0.0029
Shares Short 15,831
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 36,835
Short Name Neuphoria Therapeutics Inc.
Short Percent Of Float 0.0029
Short Ratio 0.2
Source Interval 15
State MA
Symbol NEUP
Total Cash 19,440,656
Total Cash Per Share 3.597
Total Debt 34,225
Total Revenue -13,267
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -7.9
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.53481
Two Hundred Day Average Change -2.04481
Two Hundred Day Average Change Percent -0.36944538
Type Disp Equity
Volume 44,920
Website https://www.neuphoriatx.com
Zip 1,803